SYBX stock gains after early Phase 2 data for phenylketonuria candidates (NASDAQ:SYBX)
seekingalpha.com
news
2022-10-18 17:25:37

syahrir maulana/iStock via Getty Images The clinical-stage biotech Synlogic, Inc. (NASDAQ:SYBX) jumped ~10% on Tuesday after the company reported top-line data from the Phase 2 trial for experimental oral drugs SYNB1934 and SYNB1618 in rare genetic condition phenylketonuria (PKU). PKU is characterized by the accumulation of amino acid phenylalanine in the body to neurotoxic levels. The trial named Synpheny-1 involved 20 adults with PKU, out of whom 11 were part of the SYNB1618 and nine enrolled in the SYNB1934 arm.
